EDX Medical Group has entered into an agreement with Spire Healthcare Group to advance diagnostic innovations aimed at ...

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

eXmoor Pharma and Signadori Bio have entered into a partnership aimed at advancing a gene-modified monocyte-derived ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Kallikor has announced the appointment of Chris Brett as its new Chief Technology and Product Officer. Brett holds more than ...

Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025. The company ...

In a move to progress treatment efficacy, oncologists widely agree that, in the future, cancer treatments will become ...

The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your ...

Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic ...

Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The ...

The European Migraine and Headache Alliance (EMHA) has urged EU policymakers to include migraine in the forthcoming ...